weight gain, which lead to two-thirds of patients who show improvement with treatment choosing to discontinue haloperidol. 4 Of the other several potential therapeutic antipsychotics, dopamine-blocking neuroleptics seem to be the most effective drugs for the treatment of TS, although the role of dopamine in tics is still controversial. Sulpiride is a selective dopamine D2 antagonist with antipsychotic and antidepressant activity, and is also cost-effective. In a retrospective study in 1990, Robertson et al reported a 59% reduction in severity of TS in 63 patients treated with sulpiride. 5 The mean age of the patients was 29.3 years (range, 10-68 years) and only 10 of them were treated with sulpiride as a first-line agent. In the sulpiride responders, who included adults and children, the most commonly prescribed daily dose was 400 mg. To date, this is believed to be the only study with a relatively large number of patients.
We conducted an open-label study to assess prospectively the potential effect of a lower dose of sulpiride in children and adolescents with TS or chronic tic disorder.
Patients and Methods
We recruited children and adolescents with TS or chronic tic disorder who agreed to participate in the study, and were not taking any tic-suppressing medication. Informed consent was obtained from all the parents. TS or chronic tic disorder was diagnosed by two experienced pediatric neurologists (CS Ho and NC Chiu) at our outpatient clinic be- . The severity of TS was assessed by the Yale Global Tic Severity Score (YGTSS). 6 This scale consists of ratings for motor and vocal tics, in terms of number, frequency, intensity, complexity, and interference. The YGTSS has excellent interactive reliability. 6 We rated the scores at the first clinic visit as the baseline scores and then every 2 weeks, for a total of 6 weeks of follow-up. The clinical rating at each visit was recorded by the same clinicians to avoid personal bias in severity evaluation. All the patients started with low-dose sulpiride according to their age at the first visit. For patients aged > 7 years, the initial dose was 100 mg twice daily (half a 200-mg tablet). For patients aged ≤ 7 years, the initial dose was 67 mg twice daily (a third of a 200-mg tablet). The dose was increased every 2 weeks (50-100 mg/day) if the YGTSS did not show improvement and no intolerable adverse effects were experienced. The adverse effects of sulpiride were evaluated by subjective complaint from the patients themselves or their parents, by questionnaire. At the end of the study, the average sulpiride dose in patients ≤ 7 years of age was 156 mg/day, and in patients > 7 years of age, it was 205 mg/day.
The baseline scores, including motor tic, vocal tic and total scores, were compared with the scores at weeks 2, 4 and 6. The serial score changes were analyzed by one-way analysis of variance (ANOVA), with group as a between-subject factor, to compare symptom severity at the various assessment points, measured with SPSS version 12.0 software (SPSS Inc., Chicago, IL, USA).
Results
Of the 198 patients recruited, 189 (171 children and 18 adolescents) completed the trial. Five patients were lost to follow-up and four were withdrawn from the study because they received more than one antipsychotic agent in addition to sulpiride. The mean age was 8.0 ± 2.5 years (range, 3-15 years). There were 165 male and 24 female patients. One hundred and thirteen patients fulfilled the criteria of TS, and another 71 had chronic motor tic disorder and five had chronic vocal tic disorder. At baseline, the average motor tic score evaluated by YGTSS was 12.71 ± 0.24; the average vocal tic score was 6.59 ± 0.46; and the mean total YGTSS was 32.72 ± 0.89. At the end of the study (week 6), the average motor tic score was 6.45 ± 0.59; the average vocal tic score was 2.38 ± 0.47; and the average total YGTSS was 13.36 ± 1.43. This represented a mean reduction of 49% in motor tic score, 64% in vocal tic score, and 59% in total YGTSS. Vocal tics were more responsive to sulpiride than were motor tics. All except three patients had a reduced severity score at week 6 compared with baseline. Two of the exceptions underwent examination at school and one had a common cold during therapy. In the one-way ANOVA, a significant drug effect was found between each assessment point, except between weeks 2 and 4 (Tables 1-3 ). There was a significant reduction in motor tic scores (Table 1) and total YGTSS (Table 3 ) between baseline and weeks 2, 4 and 6; however, vocal scores were only significantly reduced between baseline and week 6 ( Table 2 ). There was no significant reduction in scores between weeks 2 and 4 in motor tics, vocal tics and total YGTSS. Mean age, baseline mean score, and week 6 mean score for TS, chronic motor tic and chronic vocal tic patients are outlined in Table 4 . Compared with baseline YGTSS, significant improvement after 6 weeks of treatment was seen for motor tics (p < 0.05), vocal tics (p < 0.05) and total YGTSS (p < 0.05; Figure) . The mean initial treatment dose was 176 mg/ day and the mean treatment dose at the end of the study was 190 mg/day, which was not a significant change. The most common adverse effect with sulpiride treatment was sedation early in the trial (n = 31, 16.4%). However, in none of the patients was sedation severe enough to interfere with daily activity or school performance. The second most common adverse effect was increased appetite (n = 14, 7.4%). One patient reported a body weight gain of 2 kg after 6 weeks of treatment. The adverse effects are listed in Table 5 . None of our patients experienced extrapyramidal symptoms.
Discussion
TS is characterized by multiple motor tics plus one or more vocal (phonic) tics, which characteristically wax and wane. TS is now recognized to be associated with a wide variety of associated behaviors and psychopathology. 7 The most commonly prescribed medications for motor and vocal tics have been the dopamine antagonists. The most successful agents in this group are haloperidol, pimozide, sulpiride and tiapride, whereas risperidone and ziprasidone are two atypical neuroleptics with proven tic-suppressing efficacy.
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Haloperidol, a butyrophenone derivative, is primarily a dopamine D2 receptor blocker. 14 It is one of the most widely prescribed agents used in treating TS in the United States, Canada, United Kingdom, Europe, Australasia and the Far East. 7 However, it has been suggested that haloperidol produces unacceptable adverse effects in 84% of patients, and therefore, only a minority of 20-30% of TS patients continue treatment for extended periods. 15 Atypical neuroleptics are believed to have a low risk of tardive dyskinesia and acute extrapyramidal reactions. As a result of potential QT changes, baseline and follow-up electrocardiography is recommended for risperidone, ziprasidone and pimozide. It is also essential for the prescribing clinician to be familiar with potential cytochrome-P450-related drug reactions, because fatal interactions have arisen with pimozide and erythromycin-related antibiotics. 16 The substituted benzamides, selective D2 antagonists, have become popular for the treatment of motor and vocal tics, and produce less extrapyramidal side effects and tardive dyskinesia. 7 The most widely documented benzamide for treatment of TS is sulpiride, first used by Yvonneau and Bezard in 1970. 17 In the only double-blind trial with this drug, George et al undertook a 14-week placebo-controlled, crossover study of fluvoxamine versus sulpiride, followed by single-blind combined treatment in 11 patients with comorbid TS and obsessive-compulsive disorder (OCD). Sulpiride monotherapy greatly reduced tics and non-significantly improved OCD symptoms. 10 Robertson et al managed 63 of 114 (55%) TS patients (mean age, 29.3 years) with sulpiride, and found that beneficial effects occurred in 59% of patients. Positive effects were: decreased motor and vocal tics; OCD; aggression; echophenomena and tension; and improved mood. The dose of sulpiride in their study commenced at 200 mg/ day and increased to a limit of 1 g/day. 5 In our study, most patients were male, with a male to female ratio of 7:1, which is much higher than in previous studies, and implies that there is a male predominance in TS of unknown cause. With short-term sulpiride treatment in children with TS or chronic tic disorder, we found significant symptom reduction, which supports the findings in previous studies. As far as we are aware, our study was the second largest trial to date of sulpiride treatment in patients with TS, and was the largest study to show a good response to sulpiride in children and adolescents with TS or chronic tic disorder. The most common adverse effect of sulpiride is mild sedation, which is tolerable for all patients and often disappears at 1 or 2 weeks after treatment. No extrapyramidal symptoms were found with the low dose of sulpiride used in this study. There was no tardive dyskinesia in the study of Robertson et al, 5 which further supports our conclusion that sulpiride is a more acceptable choice than haloperidol. The limitation of our study is that most of our patients had disease of mild to moderate severity according to the YGTSS scale, and only a few patients had severe symptoms at initial presentation. This probably resulted from the younger patient age in our study than in previous studies. We could not conclude that sulpiride was effective in severe TS. However, early intervention and treatment of tics are important because long-standing symptoms may impair a patient's interpersonal relationships, academic performance, or social activities. 18 Further studies are necessary to assess the effect of sulpiride treatment in patients with severe TS.
In conclusion, sulpiride is a good short-term treatment choice for mild to moderate TS or chronic tic disorder in children and adolescents. Low-dose sulpiride is effective for treatment of TS or chronic tic disorder and has few adverse effects.
